Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : NVAX save search
Global Vaccines Market Research Report 2022-2027: A $200+ Billion Industry - Forecasts, Company Market Share and Expert Market Estimates for Vaccine Categories
Published: 2023-02-08 (Crawled : 16:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.09%
H: 1.26%
C: 0.99%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.06%
H: 0.77%
C: 0.19%
EBS | News | $2.18 -4.8% 0.0% 800K
|
Health Technology
|
| O: -0.78%
H: 0.79%
C: -5.29%
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: -0.07%
H: 4.9%
C: 2.27%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: -4.13%
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: -1.61%
H: 2.73%
C: -8.47%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -1.35%
H: 1.53%
C: 0.68%
research global report vaccine market
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 1.53%
H: 8.47%
C: -1.19%
covid-19 vaccine approved nuvaxovid
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published: 2022-08-04 (Crawled : 13:20) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 0.31%
H: 3.16%
C: 1.03%
covid-19 global children vaccine six trial phase 2b
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
Published: 2022-07-19 (Crawled : 13:00) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 1.44%
H: 13.25%
C: 10.02%
covid-19 vaccine agreement bioscience
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
Published: 2022-04-22 (Crawled : 12:00) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -12.19%
H: 4.08%
C: -1.27%
covid-19 vaccine trial phase 3
New Variants Throw the Spotlight on Booster Shots of COVID-19 Vaccines - According to New Research from StrategyR
Published: 2022-03-10 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.52%
H: 1.67%
C: 1.67%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -1.99%
H: 2.84%
C: 0.35%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -2.09%
H: 0.95%
C: 0.01%
covid-19 research covid vaccine
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
Published: 2022-01-07 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -1.88%
H: 0.0%
C: 0.0%
milestone
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 11.76%
H: 2.83%
C: -12.2%
covid-19 europe covid authorization positive vaccine
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
Published: 2021-08-30 (Crawled : 21:00) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -1.04%
H: 6.19%
C: 3.98%
covid trial covid-19
At 10.5% CAGR, Vaccine Adjuvants Market Revenue to Cross $ 1400.1 Million by 2027; Brandessence Market Research
Published: 2021-05-11 (Crawled : 12:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -16.48%
H: 9.51%
C: 3.08%
ce mark vaccine research market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.